Abstracts Archive - Page 119 of 2607 - ACR Meeting Abstracts

Abstract Number: 1546 • ACR Convergence 2025
Tacrolimus Versus Voclosporin for Active Lupus Nephritis: A Comparative Meta-analysis of Renal Response
Urvi Zala¹ and Rushi Patel², ¹Loyola MacNeal Hospital, Berwyn, IL, Oak Park, IL, ²Baptist Hospitals of Southeast Texas, Beumont, TX
Background/Purpose: Lupus nephritis (LN) is seen in approximately 40–60 % of patients with systemic lupus erythematosus (SLE) and contributes significantly to morbidity and mortality in…
Abstract Number: 1500 • ACR Convergence 2025
Prognostic Impact of Thrombocytopenia on Morbidity and Mortality in Systemic Lupus Erythematosus: A Retrospective Single-Center Study
Milad Heydari-Kamjani¹, Amir Daneshvar², Dana Nachawati², Elleson Harper², Keri Ann Pfeil², Meghan Gump², Lindsay Frumker³ and Omer Pamuk¹, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ³University hospitals Cleveland medical center, Highland Heights, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with heterogeneous hematologic manifestations. Thrombocytopenia (TP) in SLE may be associated with major organ involvement…
Abstract Number: 1522 • ACR Convergence 2025
Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database
Carlos Pena¹, Irene Tan², Rafal Ali³, Arthur Lau⁴, Shahrzad Abdollahi⁵, Fabian Rodriguez Quinonez⁶ and Marianne Meshreky⁷, ¹Jefferson Einstein Philadelphia, Wynnewood, PA, ²Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA, ³Jefferson Einstein Philadelphia, Lansdale, PA, ⁴Jefferson Einstein Hospital, Maple Glen, PA, ⁵Jefferson Einstein Hospital, Philadelphia, PA, ⁶Einstein Medical Center Philadelphia, Philadelphia, PA, ⁷St. Mary's Hospital, Philadelphia
Background/Purpose: Evidence of kidney disease occurs in up to one half of patients with SLE, and approximately 10% of the patients with lupus nephritis (LN)…
Abstract Number: 1434 • ACR Convergence 2025
Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort
Adam Mayer¹, Rui Xiao², Meenakshi Bewtra³, Michael George⁴ and Pamela Weiss⁵, ¹University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The potential that nonsteroidal anti-inflammatory drugs (NSAIDs) may precipitate flares of inflammatory bowel disease (IBD) has limited their use in managing joint pain in…
Abstract Number: 1048 • ACR Convergence 2025
Impact of Hydroxychloroquine Usage on QTc in Veterans with Rheumatic Musculoskeletal Disease
Malika Ibrahim¹, Samuel Good², Victor Tran³, David Chetrit⁴, Michael McClean⁵, Myung Shin Sim⁶, Hannah Kang¹, Jennifer Barton⁷, Meika Fang⁸, Angelo Gaffo⁹, fadi Hage¹⁰, cynthia Jackevicius⁵, Michael Pillinger¹¹, gabriela Schmajuk¹², Jasvinder Singh¹³, Alberta Warner¹⁴, Neal Yaun¹⁵ and John FitzGerald¹⁶, ¹David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Division of Rheumatology, Los Angeles, CA, ³David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Costa Mesa, CA, ⁴Carolina Health Specialists, Myrtle Beach, SC, ⁵Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, ⁶West LA VA Medical Center, Los Angeles, ⁷VA Portland Health Care System/OHSU, Portland, OR, ⁸VA Greater Los Angeles/UCLA, Los Angeles, CA, ⁹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ¹⁰VA Birmingham health care, Birmingham, AL, ¹¹New York University Grossman School of Medicine, New York,, NY, ¹²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ¹³Baylor College of Medicine, Houston, TX, ¹⁴VA Greater Los Angeles/UCLA, Los Angeles, ¹⁵UCSF / SFVA, San Francisco, ¹⁶UCLA, Los Angeles, CA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used for rheumatic diseases, but data on its cardiac safety, particularly QTc prolongation, remains limited. Concerns about HCQ inducing QTc…
Abstract Number: 1555 • ACR Convergence 2025
Prevalence of Organ Involvement and Baseline Predictors of Disease Progression in Patients with Limited Cutaneous Systemic Sclerosis: Insights from the CONQUER Database
Alain Lescoat¹, Virginia Steen², Monica Harding³, John VanBuren³, Brian Skaug⁴, Shervin Assassi⁵, Maureen Mayes⁶, Zsuzsanna McMahan⁷, Elana Bernstein⁸, Flavia Castelino⁹, Lorinda Chung¹⁰, Luke Evnin¹¹, Tracy Frech¹², Jessica Gordon¹³, Faye Hant¹⁴, Laura Hummers¹⁵, Kimberly Lakin¹³, Dorota Lebiedz-Odrobina³, Yiming Luo¹⁶, Ashima Makol¹⁷, Jerry Molitor¹⁸, Duncan Moore¹⁹, Carrie Richardson¹⁹, Nora Sandorfi²⁰, Ami Shah¹⁵, Ankoor Shah²¹, Elizabeth Volkmann²², Carleigh Zahn²³ and Dinesh Khanna²⁴, ¹CHU Rennes - University Rennes, Rennes, France, ²Georgetown University School of Medicine, Washington, DC, ³University of Utah, Salt Lake City, UT, ⁴UTHealth Houston Division of Rheumatology, Houston, TX, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁶UT Health Houston Division of Rheumatology, Houston, TX, ⁷UT Health Houston, Houston, TX, ⁸Columbia University Irving Medical Center, New York, NY, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Stanford University, Stanford, CA, ¹¹Scleroderma Research Foundation, San Francisco, CA, ¹²Vanderbilt University Medical Center, Nashville, TN, ¹³Hospital for Special Surgery, New York, NY, ¹⁴Medical University of South Carolina, Charleston, SC, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶Columbia University Irving Medical Center, New York, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸University of Minnesota, Minneapolis, MN, ¹⁹Northwestern University, Chicago, ²⁰University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ²¹Duke University, Durham, NC, ²²Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²³University of Michigan, Ann Arbor, ²⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by a wide range of clinical manifestations and available interventions still lack overall efficacy. Limited cutaneous SSc (lcSSc) and…
Abstract Number: 1279 • ACR Convergence 2025
Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Reagan Reid¹, Huayun Hou², Isha Datar², Daniela Dominguez³, Andrea Knight⁴, Deborah Levy⁵, Lawrence Ng⁶, Zhaoyu Ding², Michael Wilson², Lauren Erdman⁷, Eleanor Pullenayegum² and Linda Hiraki⁵, ¹The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²SickKids Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷University of Cincinnati, Cincinnati, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a clinically and genetically heterogeneous disease. We aimed to define subgroups of new diagnosis patients based on treatment…
Abstract Number: 1531 • ACR Convergence 2025
Achieving Remission and Low Disease Activity with Belimumab Versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
Ioannis Parodis¹, Julius Lindblom², Roger A. Levy³, Alexander Tsoi¹, Margherita Zen⁴, Dionysis Nikolopoulos⁵, Munther Khamashta⁶, Ryan Tomlinson⁷, Anca Askanase⁸, Ronald van Vollenhoven⁹ and Mandana Nikpour¹⁰, ¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁴University of Padua, Department of Medicine, Division of Rheumatology, Padua, Italy, ⁵Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁶GSK, Medical Affairs, Dubai, United Arab Emirates, ⁷GSK, Development – R&D, Collegeville, PA, ⁸Columbia University Medical Center, New York, NY, ⁹Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, ¹⁰University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia
Background/Purpose: An integrated post hoc analysis of five Phase 3 trials in adults with SLE showed greater benefit of belimumab (BEL) than placebo (PBO), plus…
Abstract Number: 1552 • ACR Convergence 2025
Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
Zahi Touma¹, Ian Bruce², Richard Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Cathy Emmas⁸, Lyra Agustin⁸, Alessandra Venerus⁹, Tarana Mehdikhanova¹⁰, Zheyuan Yang¹⁰ and Miina Waratani⁸, ¹University of Toronto, Toronto, ON, Canada, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁵AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, Gaithersburg, MD, ⁶AstraZeneca, Medical & Scientific Affairs, R&I, Mississauga, ON, Canada, ⁷AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden, ⁸AstraZeneca, BioPharmaceuticals Medical, Cambridge, United Kingdom, ⁹IQVIA, EMEA Real World Methods and Evidence Generation, Milan, Italy, ¹⁰IQVIA, EMEA Real World Methods and Evidence Generation, London, United Kingdom
Background/Purpose: Patients with systemic lupus erythematosus (SLE) can develop cardiovascular (CV) damage (angina, myocardial infarction, ventricular dysfunction, valvular disease, or pericarditis for 6 months/pericardiectomy) particularly…
Abstract Number: 1290 • ACR Convergence 2025
Adverse Childhood Experiences: Prevalence and Relationship to Disease and Mental Health Outcomes in Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Jin Xuan Zhou¹, Stephanie Fevrier², Paris Moaf², Lawrence Ng³, Asha Jeyanathan⁴, Louise Boulard², Deborah Levy¹, Linda Hiraki¹, Ashley Danguecan⁵ and Andrea Knight⁵, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Hospital for Sick Children, Toronto, Canada, ³The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease characterized by multi-organ inflammation, alongside high frequencies of mood disorders and cognitive impairment. Adverse Childhood…
Abstract Number: 1055 • ACR Convergence 2025
The Price of Relief: Examining the Role of Insurance in High-Cost Medication Use
Antara Dattagupta¹, Colin Diffie² and Sana Cheema², ¹Washington University in St. Louis, St. Louis, MO, ²Washington University in St. Louis, St. Louis
Background/Purpose: High-cost biologic therapies are integral to the management of rheumatoid arthritis (RA), yet access to these agents may be influenced by insurance type, particularly…
Abstract Number: 1561 • ACR Convergence 2025
Usefulness of HRCT in screening of interstitial lung disease in patients with systemic sclerosis without risk factors of clinical suspicion
Carlos de la Puente-Bujidos¹, Antia Garcia Fernandez², Verónica García García¹, Jesús Loarce³ and Sandra Garrote-Corral¹, ¹Ramón y Cajal University Hospital, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ³Ramón y Cajal University Hospital, Madrid, Spain
Background/Purpose: In 2019 a European expert consensus suggested that all patients with systemic sclerosis (SSc) should be screened with HRCT for interstitial lung disease (ILD)…
Abstract Number: 1265 • ACR Convergence 2025
Patient Portal Awareness and Utilization Across Diverse Rheumatology Populations
Emily Gutowski¹, Joshua Novack², Allyson Covello², Philip Carlucci³, Scott Goldberg¹, Mary Guan⁴, Marcus Hines², Elliot Philips², Michael Pillinger⁵ and Sara Stream⁶, ¹New York University Grossman School of Medicine, Brooklyn, NY, ²New York University Grossman School of Medicine, New York, NY, ³New York University School of Medicine, New York, NY, ⁴NYU Grossman SOM, Brooklyn, NY, ⁵New York University Grossman School of Medicine, New York,, NY, ⁶New York University Grossman School of Medicine, Great Neck, NY
Background/Purpose: Patients with rheumatic diseases face complex and chronic diagnoses that require close monitoring and frequent communication with their providers. Given increasing challenges to in-person…
Abstract Number: 1524 • ACR Convergence 2025
Hydroxychloroquine Reduces Autoantibody Levels in Persons at Risk for Systemic Lupus Erythematosus
David Karp¹, Prithvi Raj¹, Changsong Zhu¹, Dajiang Liu², Duanping Liao² and Nancy Olsen³, ¹UT Southwestern Medical Center, Dallas, TX, ²Penn State College of Medicine, Hershey, PA, ³Penn State University/Milton S Hershey, Hershey, PA
Background/Purpose: The Study of Antimalarials in Incomplete Lupus Erythematosus (SMILE, NCT03030118) was a double-blind, randomized, placebo-controlled study of hydroxychloroquine (HCQ) to prevent the development of…
Abstract Number: 1300 • ACR Convergence 2025
International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry
Chandni Sarker¹, Jennifer Cooper², Emily Smitherman³, Flavia Alves¹, Alexandre Belot⁴, Michael Beresford⁵, Andreea Jorgensen¹, Eve Smith⁶, Laura Lewandowski⁷ and Rebecca Sadun⁸, ¹University of Liverpool, Liverpool, United Kingdom, ²University of Colorado/Children's Hospital Colorado, Aurora, CO, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Hospices Civils de Lyon, Collonges au mont d'or, France, ⁵Alder Hey Children's NHS Foundation Trust Hospital, Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, ⁶University of Glasgow, Glasgow, United Kingdom, ⁷NIAMS, NIH, Bethesda, MD, ⁸Duke University, Durham, NC
Background/Purpose: Consensus-derived treat-to-target (T2T) goals for childhood-onset SLE (cSLE), including clinical remission on low dose steroids (cCR), have been endorsed by the Paediatric Rheumatology European…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].